RGBOQ yields 200000000.00% · JNJ yields 2.13%● Live data
📍 RGBOQ pulled ahead of the other in Year 1
Combined, RGBOQ + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RGBOQ + JNJ for your $10,000?
ReGen Biologics Inc. designs, develops, manufactures, and markets medical devices for the repair and generation of soft tissue in humans, primarily for orthopedic applications. The company's proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular, and drug delivery. Its products include Menaflex collagen meniscus implant device, for use in surgical procedures for the reinforcement and repair of soft tissue injuries of the medial meniscus; and SharpShooter Tissue Repair System, an instrument that allows surgeons to place needles in hard-to-reach locations of the meniscus. The company sells its products in the United States, the European Union, the Republic of South Africa, Canada, Australia, Chile, and Japan. ReGen Biologics Inc. was formerly known as Aros Corp and changed its name to ReGen Biologics Inc. in November, 2002. ReGen Biologics Inc. was founded in 1987 and is headquartered in Hackensack, New Jersey. On April 8, 2011, ReGen Biologics Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 14, 2011.
Full RGBOQ Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.